IB Acquisition closed at $10.81 on Nov 2, down 0.46%, 7.1% below its highest close since May 1. Volume of 3.5K shares was 1.12× its 20-day average (close to normal).
Split-adjusted performance: -0.6% over one month, -0.2% over six months.
Short interest was 2.4K shares at the Oct 15 settlement, up 2.7% from the prior report (0.3% of float, 3.1 days to cover).
No reported quarters with price history yet.
Percentile among 11 companies (100 = best)
Industry medians: 6-month return +48.1%, revenue growth +8.5%, net margin −122.0%, P/E 47.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| IBACIB Acquisition | $10.81 | −0.46% | −0.2% | — | — | — | $54.1M | |
| ONMDOneMedNet | $4.17 | −8.15% | −57.3% | +88.4% | −743.8% | — | $24.3M | Compare |
| MXCTMaxCyte | $1.31 | −5.76% | +50.3% | −14.5% | −122.0% | — | $135.2M | Compare |
| NRCNRC Health | $25.48 | −5.87% | +36.0% | +11.0% | 12.3% | 88.2 | $540.7M | Compare |
| OABIOmniAb | $4.83 | −6.76% | +228.6% | +78.3% | −393.9% | — | $704.5M | Compare |
| ISPCiSpecimen | $0.8079 | −4.16% | −84.7% | −78.7% | −896.9% | — | $2.0M | Compare |
| ABSIAbsci | $9.39 | −10.40% | +63.3% | −46.4% | −10443.4% | — | $1.61B | Compare |
| BIAFbioAffinity Technologies | $2.60 | −11.26% | −91.8% | +19.0% | −222.8% | — | $1.6M | Compare |
| CRLCharles River Laboratories International | $313.02 | −4.07% | +72.3% | −2.7% | −0.1% | — | $15.00B | Compare |
IB Acquisition Corp is a blank check company.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology